BeOne Medicines Ltd. Class A

BeOne Medicines Ltd. Class A

247.40
HKD
-2.00
(-0.80%)
3.61EPS
60.08P/E
439.40BMarket Cap
Mar 31Next Earn

Total Valuation

HKD

As of September 30, 2026, BeOne Medicines Ltd. carries a market capitalization of 439.40B, placing it among publicly traded companies globally. Its enterprise value stands at 403.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap439.40B
Enterprise Value403.06B

Important Dates

BeOne Medicines Ltd.'s next confirmed earnings release is scheduled for March 31, 2027.

Earnings Date3/31/2027

Share Statistics

As of September 30, 2026, BeOne Medicines Ltd. has 1.95B shares outstanding.

Shares Outstanding1.95B

Valuation Ratios

As of September 30, 2026, BeOne Medicines Ltd. trades at a trailing price-to-earnings ratio of 60.08. The price-to-sales ratio is 8.33, and the price-to-book ratio stands at 9.62.

PE Ratio60.08
PS Ratio8.33
PB Ratio9.62
P/TBV Ratio9.69
P/FCF Ratio39.99
P/OCF Ratio34.59

Enterprise Valuation

As of September 30, 2026, BeOne Medicines Ltd. trades at an EV/EBITDA multiple of 37.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 43.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BeOne Medicines Ltd. trades at an EV/FCF ratio of 33.76, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 403.06B versus a market cap of 439.40B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.78
EV / EBITDA37.85
EV / EBIT43.59
EV / FCF33.76

Financial Position

As of September 30, 2026, BeOne Medicines Ltd. maintains a current ratio of 3.55, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.74, indicating elevated leverage, while an interest coverage ratio of 11.80 demonstrates strong ability to service its debt obligations.

Current Ratio3.55
Quick Ratio3.10
Debt / Equity19.74
Debt / EBITDA0.85
Interest Coverage11.80

Financial Efficiency

HKD

Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. posted a return on equity (ROE) of 18.40, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.47 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.46, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.65, useful for judging operating efficiency across full business cycles. The company generates approximately 4.32M in revenue per employee across its workforce of 12,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.05 indicates how many times BeOne Medicines Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)18.40
Return on Assets (ROA)10.46
Return on Invested Capital (ROIC)15.47
Return on Capital Employed (ROCE)16.65
Revenue Per Employee4.32M
Employee Count12,000.00
Inventory Turnover1.05

Taxes

HKD

Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. recorded 1.69B in income tax expense. That works out to an effective tax rate of 19.07, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.88B, leaving 7.18B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax1.69B
Effective Tax Rate19.07

Stock Price Statistics

HKD

As of the close on November 17, 2026, BeOne Medicines Ltd.'s stock has gained approximately 14.75% over the past 52 weeks. The 50-day moving average sits at 222.87, while the 200-day moving average is 197.76.

52-Week Price Change14.75%
50-Day Moving Average222.87
200-Day Moving Average197.76

Income Statement

HKD

Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. generated 51.83B in revenue and converted that into 7.18B in net income, yielding earnings per share of 3.61. EBITDA reached 10.65B, while operating income came in at 9.25B.

Revenue51.83B
Gross Profit46.33B
Operating Income9.25B
Pretax Income8.88B
Net Income7.18B
EBITDA10.65B
EBIT9.25B
Earnings Per Share (EPS)3.61

Balance Sheet

HKD

As of September 30, 2026, BeOne Medicines Ltd. holds 45.35B in cash and equivalents against 9.01B in total debt, resulting in a net debt position of -36.93B. Total book value stands at 45.66B, with working capital of 44.70B providing operational flexibility.

Cash & Cash Equivalents45.35B
Total Debt9.01B
Net Debt-36.93B
Equity (Book Value)45.66B
Book Value Per Share23.42
Working Capital44.70B

Cash Flow

HKD

BeOne Medicines Ltd. produced 12.48B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.27B in capital expenditures, free cash flow totaled 11.21B - equivalent to 5.85 per share.

Operating Cash Flow12.48B
Capital Expenditures-1.27B
Free Cash Flow11.21B
FCF Per Share5.85

Margins

Over the twelve months ended September 30, 2026, BeOne Medicines Ltd. posted a gross margin of 89.39, reflecting its pricing power and cost economics. The operating margin of 17.84 and net profit margin of 13.86 provide insight into operational efficiency.

Gross Margin89.39
Operating Margin17.84
Pretax Margin17.12
Profit Margin13.86
EBITDA Margin20.54

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 2.50, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.47, meaning BeOne Medicines Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.47
FCF Yield2.50

Scores

As of September 30, 2026, BeOne Medicines Ltd. has an Altman Z-Score of 8.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.98